Hi, my name’s Chris Tovey and I’m GW’s Chief Operating Officer and I’m talking to you
remotely from my home office at the moment. It’s been an amazing few months, shocking in
many places as COVID 19 has sept across the world and has caused a lot of concerns and a lot of issues for many. The biggest concern for me and GW has been to ensure the continuity of supply of our important medicines and we have spent a lot of time with our manufacturing teams, increasing production actually, so I am happy to report and reassure you that we have plenty of stock and we have a strong supply chain behind us that means that patients can definitely expect to have continuity of supply of their important medicines from GW.
Our teams, our NAMS, Neurology Account Managers, and MSLs, have been working from home but I know they’ve been in touch with many of you, answering questions and supporting various programmes that you’ve got running and will continue to do this. We developed our digital technologies and platforms so that we can interact with you, so that we can provide important educational information and so that we can be there when you need us, and we’ll continue to do that. We’ll continue to evolve these platforms to meet your needs.
Finally, research. Research has taken a big hit as many clinical trials have been stopped
around the world for many companies. But what we’re continuing to do in places where we
can, is we are pressing forward with important advances in many different disease areas
where we have product candidates and we’ll do this and as we come out of COVID-19 we will be beginning to dial up our all-important research efforts and we look forward to working
with you, many of you actually, on these programmes.
So it’s a crazy time for all of us but you can guarantee that we are going to support you and
give you all the help that can to care for important patients and to navigate these difficult
times. Thank you.